[HTML][HTML] Parkinson disease-associated cognitive impairment
Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …
Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease
Concomitant Alzheimer's disease (AD) pathology is a frequent event in the context of Lewy
body disease (LBD), occurring in approximately half of all cases. Evidence shows that LBD …
body disease (LBD), occurring in approximately half of all cases. Evidence shows that LBD …
Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers
Clinical trials in dementia with Lewy bodies: the evolving c... : Current Opinion in Neurology
Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient …
Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient …
Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease
Abstract Objective Within Lewy body spectrum disorders (LBSD) with α‐synuclein pathology
(αSyn), concomitant Alzheimer's disease (AD) pathology is common and is predictive of …
(αSyn), concomitant Alzheimer's disease (AD) pathology is common and is predictive of …
CSF synaptic biomarkers in AT (N)-based subgroups of Lewy body disease
Background and Objectives Patients with Lewy body disease (LBD) often show a co-
occurring Alzheimer disease (AD) pathology. CSF biomarkers allow the detection in vivo of …
occurring Alzheimer disease (AD) pathology. CSF biomarkers allow the detection in vivo of …
Morphological characteristics differentiate dementia with Lewy bodies from Parkinson disease with and without dementia
KA Jellinger - Journal of Neural Transmission, 2023 - Springer
Dementia with Lewy bodies (DLB) and Parkinson disease (PD) with and without dementia
are entities of a spectrum of Lewy body diseases. About 26.3% of all PD patients develop …
are entities of a spectrum of Lewy body diseases. About 26.3% of all PD patients develop …
Fluid and tissue biomarkers of Lewy body dementia: report of an LBDA symposium
GD Scott, MR Arnold, TG Beach, CH Gibbons… - Frontiers in …, 2022 - frontiersin.org
The Lewy Body Dementia Association (LBDA) held a virtual event, the LBDA Biofluid/Tissue
Biomarker Symposium, on January 25, 2021, to present advances in biomarkers for Lewy …
Biomarker Symposium, on January 25, 2021, to present advances in biomarkers for Lewy …
Neuropsychological impairments and their cognitive architecture in mild cognitive impairment (MCI) with Lewy bodies and MCI-Alzheimer's disease
J Ciafone, A Thomas, R Durcan… - Journal of the …, 2022 - cambridge.org
Objective: The present study aimed to clarify the neuropsychological profile of the emergent
diagnostic category of Mild Cognitive Impairment with Lewy bodies (MCI-LB) and determine …
diagnostic category of Mild Cognitive Impairment with Lewy bodies (MCI-LB) and determine …
The diagnostic performance of functional dopaminergic scintigraphic imaging in the diagnosis of dementia with Lewy bodies: an updated systematic review
M Jreige, GK Kurian, J Perriraz, J Potheegadoo… - European Journal of …, 2023 - Springer
Introduction Dopaminergic scintigraphic imaging is a cornerstone to support the diagnosis in
dementia with Lewy bodies. To clarify the current state of knowledge on this imaging …
dementia with Lewy bodies. To clarify the current state of knowledge on this imaging …
Natural speech markers of Alzheimer's disease co-pathology in Lewy body dementias
Introduction An estimated 50% of patients with Lewy body dementias (LBD), including
Parkinson's disease dementia (PDD) and Dementia with Lewy bodies (DLB), have co …
Parkinson's disease dementia (PDD) and Dementia with Lewy bodies (DLB), have co …